ICON PLC (ICLR) Stock
ICLR has an Alpha Score of 37 out of 100 (weak), computed on Nov 2, 2026 from 3 of 4 sub-scores. 4 members of Congress disclosed 11 trades in ICLR since 2015: 5 purchases and 6 sales, most recently Kevin Hern (partial sale, Aug 14, 2026). Company insiders reported 0 open-market buys and 58 sales on SEC Form 4 in the 90 days to Nov 5, 2026. Its trailing P/E ratio is 234.5 and its net margin 0.8% (key statistics as of Nov 2, 2026).
What is ICLR's Alpha Score?
How it works →Alpha Score of 37 reflects weak overall profile with strong momentum, poor value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 2, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded ICON PLC (ICLR)?
Most recent: Kevin Hern (partial sale, Aug 14, 2026); records start May 27, 2015.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Kevin Hern R-OK · House | 2026-08-14 | partial sale | $15k – $50k |
| Kevin Hern R-OK · House | 2026-03-05 | sale | $100k – $250k |
| Julia Letlow R-LA · House | 2026-02-12 | sale | $1k – $15k |
| John James R-MI · House | 2024-09-04 | sale | $1k – $15k |
| John James R-MI · House | 2024-06-12 | purchase | $1k – $15k |
| Kevin Hern R-OK · House | 2023-01-31 | sale | $1k – $15k |
| Kevin Hern R-OK · House | 2021-09-02 | purchase | $15k – $50k |
| Kevin Hern R-OK · House | 2021-05-18 | purchase | $100k – $250k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all ICLR political trades →Are ICON PLC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 2, 26 | Clerkin Nigel Bernard John | Chief Financial Officer | SELL | 303 | $62K |
| Nov 2, 26 | Clerkin Nigel Bernard John | Chief Financial Officer | SELL | 434 | $89K |
| Nov 2, 26 | Clerkin Nigel Bernard John | Chief Financial Officer | SELL | 352 | $73K |
| Nov 2, 26 | Clerkin Nigel Bernard John | Chief Financial Officer | SELL | 377 | $78K |
| Nov 2, 26 | Clerkin Nigel Bernard John | Chief Financial Officer | SELL | 22 | $5K |
| Nov 2, 26 | Lyons Emer | Chief Accounting Officer | SELL | 54 | $11K |
| Nov 2, 26 | Lyons Emer | Chief Accounting Officer | SELL | 76 | $16K |
| Nov 2, 26 | Lyons Emer | Chief Accounting Officer | SELL | 63 | $13K |
| Nov 2, 26 | Lyons Emer | Chief Accounting Officer | SELL | 67 | $14K |
| Nov 2, 26 | Lyons Emer | Chief Accounting Officer | SELL | 4 | $838 |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →What are ICLR's key statistics?
Key statistics as of Nov 2, 2026
How does ICLR's valuation compare with the Healthcare sector?
| Metric | ICLR | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 234.5 | 28.7 | 108 |
| Net margin | 0.83% | 4.11% | 160 |
| Return on equity | 0.75% | 5.18% | 180 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 6, 2026). P/E excludes loss-making companies.
ICLR price chart
Powered by TradingViewWhat does ICON PLC do?
ICON plc is a leading global contract research organization (CRO) that provides outsourced drug and device development and commercialization services to pharmaceutical, biotechnology, medical device, and government organizations. It specializes in full-service clinical trials from Phase I to IV, including complex multinational studies, cell and gene therapy, early phase research, late phase services, and real-world evidence generation across a broad range of therapeutic areas. ICON plc offers functional service provision (FSP) solutions, embedding dedicated teams within client operations for clinical monitoring, project management, data management, and statistical programming. The company delivers innovative technology solutions, AI, and data analytics to accelerate time to market, reduce costs, and enhance trial efficiency through site- and patient-centric approaches that optimize recruitment and retention. Additional services include medical imaging, pharmacovigilance, laboratory offerings, and consulting for market access and health economics. Founded in 1990 and headquartered in Dublin, Ireland, ICON plc supports the entire product lifecycle with a global presence, enabling faster delivery of treatments that improve lives.